http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0954086-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d913bbc990f78742487267dda0639e89 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543 |
| filingDate | 1995-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75e1a21d59c2c7c6c2a4fda3c644aff3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c0fb450de77eff49266db20026ed7ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f31ddffc93247fcbe2493a529634caa |
| publicationDate | 1997-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H0954086-A |
| titleOfInvention | Hemoglobin ▲ A1C ▼ Test piece for measurement |
| abstract | (57) [Summary] [Structure] The following structures i to iv, namely, i) a hemolytic layer coated with a hemolytic agent, a denaturing agent, and microparticles ii) an agglutination layer containing anti-HbA 1C antibody iii) a function of capturing the agglutination particles Measurement layer iv) having one continuous development layer having an absorption layer for absorbing the development residual liquid in this order, v) a hemolysis layer coated with a hemolytic agent vi) measurement layer for capturing HbA vii) absorption of the development residual liquid One continuous spreading layer having an absorption layer in this order is installed side by side on one support, and the liquid can move between i and iv as well as between v and vii. A characteristic test piece for HbA 1C measurement. [Effect] HbA and HbA can be easily operated even when the patient is at home without using a large-scale analyzer and pretreatment. 1C can be measured simultaneously. Further, since the immunoagglutination reaction is used and commercially available colored beads are used, it is not necessary to label the antibody. Furthermore, since the target substance is not labeled, there is no risk of denaturing the antibody due to labeling. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008005838-A |
| priorityDate | 1995-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.